Single-chain A35R-M1R-B6R trivalent mRNA vaccines protect mice against both mpox virus and vaccinia virusResearch in context

Tianxiang Kong; Pei Du; Renyi Ma; Han Wang; Xuehui Ma; Jian Lu; Zhengrong Gao; Hai Qi; Ruiqi Li; Hao Zhang; Fei Xia; Yuanlang Liu; Ruyu Wang; Kai Duan; Zejun Wang; Qihui Wang; George F. Gao

EBioMedicine (Nov 2024)

Single-chain A35R-M1R-B6R trivalent mRNA vaccines protect mice against both mpox virus and vaccinia virusResearch in context

Tianxiang Kong,
Pei Du,
Renyi Ma,
Han Wang,
Xuehui Ma,
Jian Lu,
Zhengrong Gao,
Hai Qi,
Ruiqi Li,
Hao Zhang,
Fei Xia,
Yuanlang Liu,
Ruyu Wang,
Kai Duan,
Zejun Wang,
Qihui Wang,
George F. Gao

Affiliations

Tianxiang Kong: School of Medicine, Tsinghua University, Beijing, 100190, China; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China
Pei Du: CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China
Renyi Ma: CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China
Han Wang: College of Future Technology, Peking University, Beijing, 100871, China
Xuehui Ma: School of Medicine, Zhejiang University, Hangzhou, 310058, China; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China
Jian Lu: School of Life Sciences, Peking University, Beijing, 100871, China
Zhengrong Gao: Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China; Shenzhen Children's Hospital, Shenzhen, 518000, China
Hai Qi: School of Medicine, Tsinghua University, Beijing, 100190, China
Ruiqi Li: CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China; Savaid Medical School, University of Chinese Academy of Sciences, Beijing, 101408, China
Hao Zhang: Wuhan Institute of Biological Products Co., Ltd., Wuhan, 430207, China
Fei Xia: Wuhan Institute of Biological Products Co., Ltd., Wuhan, 430207, China
Yuanlang Liu: Wuhan Institute of Biological Products Co., Ltd., Wuhan, 430207, China
Ruyu Wang: Wuhan Institute of Biological Products Co., Ltd., Wuhan, 430207, China
Kai Duan: Wuhan Institute of Biological Products Co., Ltd., Wuhan, 430207, China
Zejun Wang: Wuhan Institute of Biological Products Co., Ltd., Wuhan, 430207, China
Qihui Wang: CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China; Savaid Medical School, University of Chinese Academy of Sciences, Beijing, 101408, China; Corresponding authors. CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China.
George F. Gao: School of Medicine, Tsinghua University, Beijing, 100190, China; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China; Savaid Medical School, University of Chinese Academy of Sciences, Beijing, 101408, China; Corresponding authors. CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China.

Journal volume & issue: Vol. 109
p. 105392

Abstract

Read online

Summary: Background: Mpox has spread to many countries around the world. While the existing live attenuated mpox vaccines are effective, advances in 21st century technologies now enable the development of vaccines with more specific antigens, clearer mechanisms, and more controllable side effects. Methods: We systematically evaluated the immunogenicity and protective efficacy of the A35R, M1R and B6R antigens of the mpox virus (MPXV). With these findings, we designed three single-chain trivalent mRNA vaccines (AMAB-wt, AMAB-C140S and AMB-C140S) by integrating the soluble regions of these antigens into single mRNA-encoded polypeptides based on their protein structures. Then, the immunogenicity and protective efficacy of these single-chain mRNA vaccines were evaluated in mice models against both VACV and MPXV. Findings: The three single-chain vaccines elicited neutralising antibodies that effectively neutralised both VACV and MPXV. The single-chain vaccines or cocktail vaccine containing mRNAs encoding soluble antigen (sA35R + sM1R + sB6R) exhibited 100% or 80% protection against a lethal dose of VACV challenge, while the cocktail of full-length antigens (A35 + M1 + B6) and the live attenuated vaccine, VACV Tian Tan (VACV-VTT), completely failed to protect mice. Moreover, the single-chain vaccines significantly reduced viral load in the lungs and ovaries of MPXV-challenged mice. Interpretation: Compared with the cocktail vaccines, our single-chain designs demonstrated similar or superior immunogenicity and protective efficacy. Importantly, the simplicity of the single-chain vaccines enhances both the controllability and accessibility of mpox vaccines. We believe these single-chain vaccines qualify as the next-generation mpox vaccines. Funding: National Natural Science Foundation of China and Youth Innovation Promotion Association of the CAS.

Published in EBioMedicine

ISSN: 2352-3964 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Medicine (General)
Website: http://www.journals.elsevier.com/ebiomedicine/

About the journal

Abstract

Keywords